Unaudited financial (Standalone and consildated) results for the half year ended 30th September 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 2.0 pts less than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indrayani Biotech reported consolidated Q2 FY26 revenue of ₹3,774.98 lakhs, up about 25% from ₹3,015.99 lakhs in Q2 FY25, while H1 FY26 revenue grew to ₹6,790.97 lakhs (₹6,268.65 lakhs in H1 FY25). The company swung back to a consolidated profit after tax of ₹106.87 lakhs in H1 FY26 from a loss of ₹610.75 lakhs in H1 FY25, with standalone H1 PAT at ₹59.60 lakhs. However, operating cash flow was deeply negative at about ₹(1,017) lakhs consolidated, driven by working capital outflows and increased borrowings. Total consolidated borrowings rose to ₹14,631.75 lakhs against equity of ₹10,381.70 lakhs, pushing the debt-to-equity ratio above 1.4. The auditor issued an unmodified opinion. Separately, a non-executive director resigned citing personal reasons, and the board acknowledged a ₹16,520 BSE fine for delayed appointment of a compliance officer, which has since been paid.
The Q2 revenue rebound and return to profitability are positive signals, but the steeply negative operating cash flow and rising leverage (D/E above 1.4) raise concerns about near-term liquidity and capital structure. Investors should watch for working capital improvement and debt reduction in upcoming quarters; the director exit and compliance penalty are minor governance items already resolved.